| Mediator of acute inflammation | | |
| Mediator of chronic inflammation | | |
| Cell type: source for the chronic inflammation mediator TNF alpha | | |
| Primary Effect of TNF alpha in chronic inflammation: | | |
| May slow bone damage associated with rheumatoid arthritis | | |
| Reduces pharmacological activity of spironolactone, competes with penicillin G. for renal tubular secretion;inhibits probenecid uricosuric effect | | |
| Celecoxib | | |
| Salicylate, but less effective than aspirin as cyclooxygenase inhibitors | | |
| Transaminitis (increase serum aminotransferase) | | |
| Infusion of this drug: accelerates closure of patent ductus arteriosus in premature newborns | | |
